Finegoldia magna PpL Specific Neutra™ Antibody Products

Are prolonged timelines in combating antibiotic-resistant infections hindering your progress? Creative Biolabs' F. magna PpL specific Neutra™ antibody Products overcome these challenges with precision-engineered monoclonal antibodies, enabling rapid targeting of bacterial virulence mechanisms to accelerate therapeutic discovery.

Introduction to F. magna PpL

Finegoldia magna, a Gram-positive anaerobic coccus, is a commensal bacterium of the human microbiota that becomes pathogenic under immunocompromised conditions. Its surface-exposed Protein L (PpL), a multidomain virulence factor, binds host immunoglobulins via interactions with kappa light chains, disrupting immune recognition and promoting bacterial evasion.

• Structural Insights

F. magna PpL contains five homologous Ig-binding B repeats. Each repeat folds into a β-sheet-rich structure stabilized by disulfide bonds, facilitating high-affinity interactions with kappa chains. The N-terminal domain mediates adhesion to host extracellular matrix components, while the C-terminal region anchors PpL to the bacterial cell wall. Cryo-EM studies reveal dynamic conformational changes in PpL during IgG binding, underscoring its role in immune interference.

• Immune Evasion and Pathogenicity

PpL disrupts adaptive immunity by:

1. Neutralizing circulating IgG via non-antigen-specific binding, impairing opsonization.

2. Inhibiting B-cell receptor signaling through kappa chain cross-linking, suppressing antibody production.

3. Activating complement regulators like CD55 to block membrane attack complex formation.

These mechanisms enable F. magna to persist in chronic infections such as osteomyelitis, prosthetic joint infections, and diabetic foot ulcers.

• Clinical Relevance

F. magna is implicated in polymicrobial biofilm-associated infections, particularly in post-surgical and diabetic patients. Its resistance to conventional antibiotics and ability to evade immune clearance contribute to high recurrence rates. Targeting PpL disrupts bacterial survival strategies, offering a novel therapeutic avenue.

Fig.1 Role of F. magna in the host defenses.¹

Applications of F. magna PpL Neutralizing Antibodies

• Therapeutic Development Against Chronic Infections

Anti-PpL antibodies directly counteract immune evasion, restoring opsonophagocytosis and enhancing bacterial clearance. In combination with antibiotics, they reduce treatment duration in biofilm-driven infections. Early-phase trials highlight their potential to lower relapse rates in diabetic wound infections.

• Diagnostic Assay Optimization

PpL-specific antibodies improve detection sensitivity in ELISA-based assays, enabling rapid identification of F. magna in clinical samples. Their high specificity minimizes cross-reactivity with other biofilm-forming pathogens, aiding accurate diagnosis of polymicrobial infections.

• Immune Modulation Studies

Researchers utilize these antibodies to dissect PpL's immunosuppressive effects. In vitro, they reverse B-cell anergy induced by PpL, providing insights into host-pathogen interactions and guiding immunotherapy design.

• Vaccine Adjuvant Development

Anti-PpL antibodies enhance antigen presentation when co-administered with bacterial antigens, boosting vaccine-induced humoral responses. This adjuvant effect is being explored in preclinical models for prophylactic vaccines against opportunistic pathogens.

Our Anti-F. magna PpL Antibodies

Creative Biolabs' antibodies are engineered to block PpL-IgG interactions with sub-nanomolar affinity. Validated in functional neutralization assays, they enable:

- Epitope-Specific Neutralization: Antibodies target the B repeat domain, preventing kappa chain binding without cross-reacting with human proteins.

- Biofilm Disruption: Anti-PpL antibodies reduce bacterial adherence and biofilm integrity in vitro, enhancing susceptibility to antibiotics.

- In Vivo Efficacy: Preclinical models demonstrate reduced bacterial load and inflammation in soft tissue infections following antibody administration.

Creative Biolabs' F. magna PpL specific Neutra™ antibodies deliver unmatched specificity and reproducibility for infection research and therapeutic development. Customizable for ELISA, flow cytometry, and in vivo models, these tools empower breakthroughs in combating antibiotic-resistant infections.

Contact our scientific team today to discuss your project requirements.

REFERENCE

1. Durand, Benjamin ARN, et al. "Bacterial interactions in the context of chronic wound biofilm: a review." Microorganisms 10.8 (2022): 1500. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/microorganisms10081500